Oyster Point Pharma

$20.58
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.10 (+0.49%) Today
$0.00 (0.00%) As of 8:00 PM UTC after-hours

Why Robinhood?

You can buy or sell OYST and other stocks, options, and ETFs commission-free!

About OYST

Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.

CEO
Jeffrey A. Nau
Employees
62
Headquarters
Princeton, New Jersey
Founded
2015
Market Cap
530.94M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
94.82K
High Today
$20.83
Low Today
$20.02
Open Price
$20.37
Volume
28.96K
52 Week High
$36.90
52 Week Low
$17.24

OYST Earnings

-$8.10
-$5.40
-$2.70
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 11, After Hours

You May Also Like

EVK
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure